Tesamorelin improves fat quality independent of changes in fat quantity.

ABSTRACT:

Objectives

Fat quality and quantity may affect health similarly or differently. Fat quality can be assessed by measuring fat density on CT scan (greater density = smaller, higher quality adipocytes). We assessed the effects of tesamorelin, a growth hormone-releasing hormone analogue that reduces visceral fat (VAT) quantity in some people living with HIV (PWH), on fat density.

Design

Participants from two completed, placebo-controlled, randomized trials of tesamorelin for central adiposity treatment in PWH were included if they had either a clinical response to tesamorelin (VAT decrease ≥8%, ≈70% of participants) or were placebo-treated.

Methods

CT VAT and subcutaneous fat (SAT) density (Hounsfield Units, HU) were measured by a central blinded reader.

Results

Pa

SUBMITTER: Lake JE 

PROVIDER: S-EPMC8243807 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature